ABSTRACT
After the spread of SARS-CoV-2 epidemic out of China, the world approaches the 2 million declared infected cases and death toll rises well above the 100 thousand. The course of pandemic evolution has shown great differences among countries and not much is yet known about the level of generated immunity, which might appear not to be long-lasting. In this situation, management of a recurrent disease seems to be a plausible scenario that countries worldwide will have to face, before effective drugs or a vaccine appear. Spain in Europe, appears to be the first country deciding to partly lift the strict social distancing regulations imposed. Whether this action may lead to further epidemic recrudescence, to a following second wave of cases or conversely, help return to previous normality, is a subject of great debate and interest to all other countries affected by COVID-19. Here we applied a modified SEIR compartmental model accounting for the spread of infection during the latent period, in which we had also incorporated effects of social confinement. We now modify this previous model configuration to mimic potential post-confinement scenarios, by simulating from instant massive liberation of different portions of the confined population, up to a more gradual incorporation of people to work. Results show how current lockdown conditions should be extended at least two weeks more to prevent a new escalation in cases and deaths, as well as a larger second wave occurring in just a few months. Conversely, best-case scenario in terms of lower COVID-19 incidence and casualties should gradually incorporate workers back in a daily proportion at most 30 percent higher than that of previous confinement. The former should begin not earlier than by the end of April and it would represent approximately 600 thousand people or a 3.75% rate for the whole of Spain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* leonardorafael.lopez{at}isglobal.org, xavier.rodo{at}isglobal.org
Data Availability
All the data included in this manuscript is available in public repositories.
https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/home.htm